The registry platform, which specializes in preventing duplicate enrollment and protocol violations, will utilize the fresh capital to bolster its infrastructure and geographic reach. While the company maintains its current branding and commitments to data integrity, the influx of resources aims to deepen its impact on sponsors, research sites, and clinical trial participants. The company’s core technology remains a critical safeguard against the risks of study failure and compromised research quality.

Howard Miller arrives with over three decades of experience in the life sciences sector, including leadership tenures at Envision Pharma Group and Two Labs. Co-founders Dr. Mitchell Efros and Kerri Weingard will transition into new strategic roles; Efros becomes President, focusing on client relationships, while Weingard assumes the position of Chief of Strategic Operations to oversee scaling efforts. WindRose partner CJ Burnes noted that the firm’s investment targets the company’s ability to reduce downstream clinical risks and improve safety standards across the pharmaceutical services landscape.